A fresh look at the molecular pharmacology of plasminogen activators: From theory to test tube to clinical outcomes

American Journal of Health-System Pharmacy

Volumn 54, Issue SUPPL. 1, 1997, Pages

  Smalling, Richard W ^a,b  

^a University of Texas Houston McGovern Medical School   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

Alteplase; Mechanism of action; N PA; Reteplase; Thrombolytic agents; TNK t PA

Indexed keywords

ALTEPLASE; PLASMINOGEN ACTIVATOR; STREPTOKINASE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CONFERENCE PAPER; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; FIBRINOLYTIC THERAPY; GENETIC ENGINEERING; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030721728     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.suppl_1.s17     Document Type: Conference Paper

References (49)

1. American Heart Association. 1997 statistical supplement. Dallas: American Heart Association; 1997.
2. Reimer KA, Lowe JE, Rasmussen MM et al. The wavefront phenomenon of ischemic cell death. I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977; 56:786-94.
3. Weaver WD, Cerqueira M, Hallstrom AP et al. Perihospital-initiated vs hospital-initiated thrombolytic therapy. JAMA. 1993; 270:1211-6.
4. Linderer T, Schröder R, Arntz R et al. Prehospital thrombolysis: beneficial effects of very early treatment on Infarct size and left ventricular function. J Am Coll Cardiol. 1993; 22:1304-10.
5. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993; 342:759-66.
6. Dalen JE, Gore JM, Braunwald E et al. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Am J Cardiol. 1988; 62:179-85.
7. Ohman EM, Califf RM, Topol EJ et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990; 82:781-91.
8. Lamas GA, Flaker GC, Mitchell G et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation. 1995; 92:1101-9.
9. Anderson JL, Karagounis LA, Becker LC et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Circulation. 1993; 87:1829-39.
10. Vogt A, von Essen R, Tebbe U et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of our German multicenter studies. J Am Coll Cardiol. 1993; 21:1391-5.
11. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329:1615-22.
12. Simes RJ, Topol EJ, Holmes DR Jr et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995; 91:1923-8.
13. Smalling RW, Fuentes F, Freund GC et al. Beneficial effects of intracoronary thrombolysis up to eighteen hours after onset of pain in evolving myocardial infarction. Am Heart J. 1982; 104:912-20.
14. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial Infarction. Lancet. 1986; 1:397-401.
15. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987; 2:871-4.
16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988; 2:349-60.
17. Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987; 76:142-54.
18. Topol EJ, Morris DC, Smalling RW et al. A multicenter, randomized placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol. 1987; 9:1205-13.
19. Neuhaus KL, von Essen R, Vogt A et al. Dose finding with a novel recombinant plasminogen activator (BM 06. 022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. J Am Coll Cardiol. 1994; 24:55-60.
20. Smalling RW, Schumacher R, Morris D et al. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage requirements. J Am Coll Cardiol. 1990; 15:915-21.
21. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990; 336:65-71.
22. ISIS-3 (Third International Study of Infarct Survival) Collab- orative Group. ISIS-3: a randomised comparison of strep- tokinase vs, tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992; 339:753-70
23. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329:673-82.
24. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial Infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990; 336:71-5.
25. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol. 1996; 78(suppl 12A):2-7.
26. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction: a review. Drugs. 1992; 44:293-325.
27. Gore JM, Sloan M, Price TR et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Circulation. 1991; 83:448-59.
28. Gore JM, Granger CB, Simoons ML et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-1 trial. Circulation. 1995; 92:2811-8.
29. Simoons ML, Maggioni AP, Knatterud G et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993; 342:1523-8.
30. Loscalzo J. Molecular biologic modification of plasminogen activators, an artful science. Circulation. 1990; 82:1062-3.
31. Collen D, Lijnen HR, Gold HK. Towards better thrombolytic therapy. Pros Cardiovasc Dis. 1991; 34:101-12.
32. Brieger D, Topol EJ. In: Califf RM, ed. Thrombolytic therapy: new standards of care. Part 1. Belle Mead, NJ: Excerpta Medica; 1996:16-22.
33. Kohnert U, Hellerbrand K, Martin U et al. The recombinant Escherichia coli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis. 1996; 1-10. Abstract.
34. Martin U, Bader R, Bohm E et al. BM 06. 022: a novel recombinant plasminogen activator. Cardiovasc Drug Rev. 1993; 11:299-311.
35. Kohnert U, Rudolph R, Verheijen JH et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06. 022. Protein Eng. 1992; 5:93-100.
36. Martin U, Fischer S, Kohnert U et al. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06. 022) in a canine model. J Cardiovasc Pharmacol. 1991; 18:111-9.
37. Martin Y, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06. 022 compared with alteplase, anistreplase, streptokinase and urokinase In a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992; 19:433-40.
38. Tebbe U, von Essen R, Smolarz A et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06. 022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol. 1993; 72:518-24.
39. Neuhaus KL, Feuerer W, Jeep-Tebbe S et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989; 14:1566-9.
40. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995; 346:329-36.
41. Smalling RW, Bode C, Kalbfleisch J et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995; 91:2725-32.
42. Bode C, Smalling RW, Berg G et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996; 94:891-8.
43. Keyt BA, Paoni NF, Refino CJ et al. A faster-acting and more. potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994; 91:3670-4.
44. Thomas GR, Thibodeaux H, Errett CJ et al. A long half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 1994; 25:2072-9.
45. Benedict CR, Refino CJ, Keyt BA et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995; 92:3032-40.
46. Braunwald E et al. TNK EPA. Proc Thromb Collegium. In press.
47. Larsen GR, Timony GA, Horgan PG et al. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem. 1991; 266:8156-61.
48. Ohman EM. Trials in acute myocardial infarction. J Myocard Ischemia. 1994; 6:24-31.
49. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996; 335:775-82.